FLSM
Frazier Life Sciences Management Portfolio holdings
AUM
$2.5B
This Quarter Return
+13.35%
1 Year Return
+52.94%
3 Year Return
+530.54%
5 Year Return
–
10 Year Return
–
AUM
$2.41B
AUM Growth
+$2.41B
(-3.4%)
Cap. Flow
-$42.5M
Cap. Flow
% of AUM
-1.77%
Top 10 Holdings %
Top 10 Hldgs %
66.5%
Holding
55
New
2
Increased
13
Reduced
9
Closed
5
Top Buys
| 1 |
NewAmsterdam Pharma
NAMS
|
$78.7M |
| 2 |
Pliant Therapeutics
PLRX
|
$14.8M |
| 3 |
Trevi Therapeutics
TRVI
|
$13.5M |
| 4 |
KalVista Pharmaceuticals
KALV
|
$10.2M |
| 5 |
PVLA
Palvella Therapeutics, Inc. Common Stock
PVLA
|
$7.66M |
Top Sells
| 1 |
Edgewise Therapeutics
EWTX
|
$41.7M |
| 2 |
Krystal Biotech
KRYS
|
$31.3M |
| 3 |
Rhythm Pharmaceuticals
RYTM
|
$30.6M |
| 4 |
Vaxcyte
PCVX
|
$27.8M |
| 5 |
Tyra Biosciences
TYRA
|
$17.2M |
Sector Composition
| 1 | Healthcare | 99.7% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
|
1
NewAmsterdam Pharma
NAMS
$2.71B
| $409M | 16.98% | 15,916,418 +3,061,224 | +24% | +$78.7M |
|
2
Mirum Pharmaceuticals
MIRM
$3.71B
| $272M | 11.28% | 6,570,392 | – | – |
|
|
VRNA
3
Verona Pharma
VRNA
$9.16B
| $157M | 6.52% | 3,383,950 | – | – |
|
|
4
Krystal Biotech
KRYS
$4.27B
| $124M | 5.13% | 788,460 -200,000 | -20% | -$31.3M |
|
5
Arcutis Biotherapeutics
ARQT
$1.86B
| $122M | 5.08% | 8,785,284 | – | – |
|
6
Disc Medicine
IRON
$2.07B
| $111M | 4.62% | 1,754,834 | – | – |
|
|
MBX
7
MBX Biosciences, Inc. Common Stock
MBX
$507M
| $110M | 4.58% | 5,985,347 | – | – |
|
|
8
Rhythm Pharmaceuticals
RYTM
$6.85B
| $105M | 4.34% | 1,869,808 -547,144 | -23% | -$30.6M |
|
9
BridgeBio Pharma
BBIO
$9.89B
| $104M | 4.33% | 3,800,457 +40,000 | +1% | +$1.1M |
|
10
Tarsus Pharmaceuticals
TARS
$2.47B
| $87.9M | 3.65% | 1,587,527 | – | – |
|
11
Phathom Pharmaceuticals
PHAT
$864M
| $82.1M | 3.41% | 10,109,279 | – | – |
|
12
Erasca
ERAS
$445M
| $48.7M | 2.02% | 19,391,687 | – | – |
|
|
13
Vaxcyte
PCVX
$4B
| $44.2M | 1.83% | 539,405 -340,000 | -39% | -$27.8M |
|
|
14
Trevi Therapeutics
TRVI
$883M
| $43.9M | 1.82% | 10,664,774 +3,283,684 | +44% | +$13.5M |
|
15
Revolution Medicines
RVMD
$7.1B
| $43.6M | 1.81% | 997,455 | – | – |
|
|
16
KalVista Pharmaceuticals
KALV
$678M
| $41.4M | 1.72% | 4,887,867 +1,200,000 | +33% | +$10.2M |
|
17
Agios Pharmaceuticals
AGIO
$2.19B
| $35.2M | 1.46% | 1,069,754 +25,600 | +2% | +$841K |
|
|
18
Edgewise Therapeutics
EWTX
$1.51B
| $33.9M | 1.41% | 1,271,245 -1,561,622 | -55% | -$41.7M |
|
19
Soleno Therapeutics
SLNO
$3.6B
| $31.4M | 1.3% | 699,159 -176,508 | -20% | -$7.93M |
|
20
Oric Pharmaceuticals
ORIC
$994M
| $31.4M | 1.3% | 3,888,238 -254,617 | -6% | -$2.05M |
|
21
Ultragenyx Pharmaceutical
RARE
$2.89B
| $27.7M | 1.15% | 658,715 +25,000 | +4% | +$1.05M |
|
22
Savara
SVRA
$567M
| $26.6M | 1.1% | 8,660,379 +502,994 | +6% | +$1.54M |
|
23
CG Oncology
CGON
$2.04B
| $22.1M | 0.92% | 770,000 | – | – |
|
24
HilleVax
HLVX
$105M
| $22M | 0.91% | 10,617,062 | – | – |
|
25
AnaptysBio
ANAB
$569M
| $20.8M | 0.86% | 1,573,719 -635,470 | -29% | -$8.41M |
|